Valeria Santini, MD

Articles

Unmet Needs and Future of Lower-Risk MDS

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Treatment Strategies and Sequencing in MDS

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Real-World Data for Luspatercept in Lower-Risk MDS

October 12th 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

October 5th 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

October 5th 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

September 28th 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

September 28th 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Clinical Insights into the COMMANDS Trial

September 21st 2023

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

September 21st 2023

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.